FDA approves Vonvendi for the treatment of von Willebrand Disease
9 December 2015 | By Victoria White
Vonvendi [von Willebrand factor (Recombinant)] is the first and only recombinant treatment for adults living with von Willebrand Disease (VWD)...
List view / Grid view
News
FDA approves Alexion’s Kanuma for LAL deficiency
9 December 2015 | By Victoria White
Kanuma (sebelipase alfa) has been approved for the treatment of patients with a diagnosis of lysosomal acid lipase deficiency (LAL-D)...
AML treatment market to reach $932.6 million by 2024
9 December 2015 | By Victoria White
The treatment market for acute myeloid leukaemia (AML) will rapidly expand in value from $342.7 million in 2014 to reach $932.6 million by 2024, says research and consulting firm GlobalData.
Repurposed ebselen shows promise in bipolar trial
9 December 2015 | By Victoria White
In a small trial, where healthy adult volunteers were given a course of ebselen, the results showed that ebselen had similar effects on the brain to lithium...
Researchers create World’s first ibuprofen patch
9 December 2015 | By Victoria White
The ibuprofen patch delivers the drug directly through skin to exactly where it is needed at a consistent dose rate...
Gilead announces interim Phase 3 results of idelalisib in CLL
8 December 2015 | By Victoria White
The analysis found a 67% reduction in the risk of disease progression or death in patients receiving idelalisib plus bendamustine and rituximab (BR) compared to placebo plus BR...
EMA grants Orphan Drug Designation for Debio 1143
8 December 2015 | By Victoria White
Debio1143 is an oral, small molecule inhibitor of IAPs with a dual pro-apoptotic and immunomodulatory mode of action developed as a potent chemo/radiosensitiser in ovarian cancer...
MGB Biopharma completes Phase I trial of MGB-BP-3
8 December 2015 | By
MGB-BP-3 is an antibiotic that is being developed for the potential treatment of Clostridium difficile infections...
Eisai presents new data for perampanel at AES 2015
8 December 2015 | By Victoria White
New data, presented at AES 2015, show that Eisai's Fycompa (perampanel) treatment reduces primary and secondary generalised tonic clonic seizures and is well tolerated versus placebo...
CTL019 demonstrates 93% remission in paediatric patients with r/r ALL
8 December 2015 | By Victoria White
This finding comes from from an ongoing Phase II study of CTL019 and, Novartis says, further support its potential in the treatment of paediatric patients with relapsed/refractory acute lymphoblastic leukaemia...
EMA accepts MAA for Sandoz’s biosimilar etanercept
8 December 2015 | By Victoria White
Sandoz is seeking approval for all indications included in the label of the reference product which is used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis...
Real world data for eslicarbazepine acetate presented at AES
7 December 2015 | By Victoria White
The data shows that a good proportion of people with partial-onset seizures, who have not responded when treated with carbamazepine, may respond to eslicarbazepine acetate...
Takeda announces new data for Adcetris in Hodgkin lymphoma
7 December 2015 | By Victoria White
Takeda presented long-term data from a Phase II and Phase III trial of Adcetris (brentuximab vedotin) at the 57th American Society of Hematology (ASH) annual meeting...
Empliciti efficacy benefits demonstrated in extended follow-up data
7 December 2015 | By Victoria White
The follow-up data demonstrated that Empliciti (elotuzumab) in combination with Revlimid (lenalidomide) and dexamethasone had an improvement in progression-free survival in patients with relapsed or refractory multiple myeloma...
Mutations in CLL suggest potential new uses for existing cancer drugs
7 December 2015 | By Victoria White
By mining the DNA of patients with chronic lymphocytic leukaemia (CLL), researchers at Penn Medicine have uncovered 12 mutations that may be targetable using therapies already available for other cancers...
